Tardive dyskinesia

Teva to Present New Data at The MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience Evaluating Long-Term Treatment with AUSTEDO® (deutetrabenazine) Tablets

Retrieved on: 
Monday, September 14, 2020
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Organ systems, Neurological disorders, Huntington's disease, Nervous system, Health, RTT, Syndromes, Tardive dyskinesia, Deutetrabenazine, Chorea, Movement disorders, Differential diagnoses of depression, AUSTEDO® (deutetrabenazine), Teva

All abstracts presented at MDS Virtual Congress 2020 will be published in the Movement Disorders journal e-supplement and displayed as an e-poster in the 2020 Virtual Poster.

Key Points: 
  • All abstracts presented at MDS Virtual Congress 2020 will be published in the Movement Disorders journal e-supplement and displayed as an e-poster in the 2020 Virtual Poster.
  • Abstracts at the Psych Congress 2020 Virtual Experience will be available online in the virtual exhibit hall.
  • AUSTEDO is indicated for the treatment of chorea associated with Huntingtons disease and for the treatment of tardive dyskinesia in adults.
  • AUSTEDO is contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience

Retrieved on: 
Tuesday, September 8, 2020
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Huntington's disease, Organ systems, Health, Neurological disorders, Articles, Deutetrabenazine, Syndromes, RTT, Tardive dyskinesia, Teva Pharmaceuticals, The Movement Disorder Society, Tetrabenazine

Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new study data on AUSTEDO (deutetrabenazine) will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience.

Key Points: 
  • Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new study data on AUSTEDO (deutetrabenazine) will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience.
  • All abstracts presented at MDS Virtual Congress 2020 will be published in the Movement Disorders journal e-supplement and displayed as an e-poster in the 2020 Virtual Poster Hall.
  • Abstracts at the Psych Congress 2020 Virtual Experience will be available in the virtual exhibit hall.
  • AUSTEDO is indicated for the treatment of chorea associated with Huntingtons disease and for the treatment of tardive dyskinesia in adults.

Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings

Retrieved on: 
Thursday, September 3, 2020
Branches of biology, Neurological disorders, Organ systems, RTT, Syndromes, Tardive dyskinesia, Neurocrine Biosciences, Valbenazine, Parkinson's disease, Tardive, Vesicular monoamine transporter, Antipsychotic

"We are excited to present new data at this year's Psych Congress and MDS that illustrate the depth and breadth of our movement disorder programs for tardive dyskinesia and Parkinson's disease in clinical research," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.

Key Points: 
  • "We are excited to present new data at this year's Psych Congress and MDS that illustrate the depth and breadth of our movement disorder programs for tardive dyskinesia and Parkinson's disease in clinical research," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons.
  • Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with psychiatric medications such as antipsychotics or antidepressants.
  • The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas.

Impact of Baseline Dyskinesia on Safety and Efficacy of NOURIANZ® (istradefylline) in Patients with Parkinson's Disease Presented During "Virtual" European Academy of Neurology Meeting

Retrieved on: 
Tuesday, May 26, 2020
Organ systems, Organic compounds, Neurological disorders, Parkinson's disease, Nervous system, Istradefylline, Xanthines, Adenosine A2A receptor, Dyskinesia, Amines, Levodopa-induced dyskinesia, Tardive dyskinesia

These findings were presented during the 6th Congress of the European Academy of Neurology (EAN).

Key Points: 
  • These findings were presented during the 6th Congress of the European Academy of Neurology (EAN).
  • "The results being presented at EAN suggest that dyskinesia is observed more often in patients with baseline dyskinesia before istradefylline was added to the treatment regimen and that the overall efficacy of istradefylline was not affected by patients' baseline status.
  • While these data provide further information, physicians should continue to monitor patients for dyskinesia or exacerbation of existing dyskinesia during NOURIANZ treatment.
  • Impact of Baseline Dyskinesia on the Safety and Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, in Patients with Parkinson's Disease: a Pooled Analysis of 8 Clinical Studies.

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

Retrieved on: 
Monday, May 18, 2020
Health, Pharmaceutical, Branches of biology, Organ systems, Nervous system, Neurological disorders, Amphetamine, Huntington's disease, Tardive dyskinesia, Neurotransmitter transporters, Deutetrabenazine, Teva Pharmaceutical Industries, Vesicular monoamine transporter, Movement disorders, Huntington's Disease, Tardive Dyskinesia, AUSTEDO® (deutetrabenazine), Teva

This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.

Key Points: 
  • This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.
  • The approval of AUSTEDO in China is an exciting milestone for Teva," said Gianfranco Nazzi, Executive Vice President, International Markets, at Teva.
  • Tardive dyskinesia is a movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, trunk and extremities.
  • AUSTEDO is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntingtons disease.

Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform

Retrieved on: 
Wednesday, May 13, 2020
Branches of biology, Amphetamine, Biogenic amines, Neurotransmitter transporters, Receptors, Signal transduction, Neurocrine Biosciences, Neurocrine, Tardive dyskinesia, Dopamine, Vesicular monoamine transporter 2, Vesicular monoamine transporter

SAN DIEGO, May 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Platform beginning May 18, 2020.

Key Points: 
  • SAN DIEGO, May 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Platform beginning May 18, 2020.
  • "We look forward to presenting data from our movement disorder programs for tardive dyskinesia and Parkinson's disease at the AAN Science Highlights platform," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release from presynaptic neurons.

Neurocrine Biosciences Announces New Data Published from the Largest Real-World Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disord

Retrieved on: 
Thursday, May 7, 2020
Organ systems, Neurological disorders, Nervous system, Health, Tardive dyskinesia, Movement disorders, Neurocrine Biosciences, Psychiatry, Sulpiride

"Many patients reported that involuntary movements from possible tardive dyskinesia impact their ability to talk, socialize and be productive, leaving many of them feeling self-conscious or embarrassed.

Key Points: 
  • "Many patients reported that involuntary movements from possible tardive dyskinesia impact their ability to talk, socialize and be productive, leaving many of them feeling self-conscious or embarrassed.
  • These data support the continued need to raise awareness of involuntary movements from possible tardive dyskinesia and the importance of properly screening, diagnosing and helping to relieve the suffering that many of these patients are experiencing."
  • RE-KINECT, a prospective real-world screening study that included 739 patients from 37 outpatient psychiatry practices in the U.S., was conducted with support from Neurocrine Biosciences.
  • Patients were clinically evaluated for abnormal involuntary movements in general body regions (head/face, neck/trunk, upper/lower limbs) as well as for possible TD.

Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease

Retrieved on: 
Tuesday, February 11, 2020
Neurological disorders, Organ systems, Nervous system, Levodopa-induced dyskinesia, Dyskinesia, Parkinson's disease, L-DOPA, Tardive dyskinesia

These results expand not only our knowledge of GOCOVRI efficacy but also of its long-term safety in these patients.

Key Points: 
  • These results expand not only our knowledge of GOCOVRI efficacy but also of its long-term safety in these patients.
  • These newly published results suggest that GOCOVRI may reduce dyskinesia and OFF as far out as 100 weeks, providing sustained benefits to patients with levodopa-induced dyskinesia.
  • Given the chronic nature of Parkinsons disease, both patients and physicians seek treatments that are effective long-term, said Jean Hubble, MD, Vice President of Medical Affairs for Adamas.
  • Published in the Journal of Parkinsons Disease, online in pre-press mode ahead of publication of the issue.

Upsher-Smith Launches Haloperidol Tablets, USP

Retrieved on: 
Monday, January 13, 2020
RTT, Psychoactive drugs, Drugs, Chemical compounds, Haloperidol, Antipsychotic, Atypical antipsychotic, Psychosis, Typical antipsychotic, Boxed warning, Dementia, Tardive dyskinesia

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

Key Points: 
  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality.
  • Haloperidol is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).
  • Please refer to the full Prescribing Information, including Boxed Warning for Haloperidol Tablets, USP here .

Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Retrieved on: 
Friday, October 4, 2019
Neurological disorders, RTT, Medicine, Syndromes, Tardive dyskinesia, Health, Tardive, Nervous system

These long-term INGREZZA data were presented today at the 2019 Annual Psych Congress in San Diego.

Key Points: 
  • These long-term INGREZZA data were presented today at the 2019 Annual Psych Congress in San Diego.
  • "Long-term data from the pooled analyses are important as they show that the 40 mg dose of INGREZZA is effective in reducing the troublesome movements of tardive dyskinesia in over 50% of patients.
  • Additionally, dose reductions from 80 mg to 40 mg did not appear to compromise the long-term benefit of INGREZZA.
  • These statements include, but are not limited to, statements related to the benefits to be derived by patients from INGREZZA.